Brodimoprim
From Wikipedia, the free encyclopedia
 |
|
|
Brodimoprim
|
|
| Systematic (IUPAC) name | |
| 5-[(4-bromo-3,5-dimethoxyphenyl)methyl] pyrimidine-2,4-diamine |
|
| Identifiers | |
| CAS number | ? |
| ATC code | J01 |
| PubChem | |
| Chemical data | |
| Formula | C13H15BrN4O2 |
| Mol. mass | 339.188 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Brodimoprim is a structural derivative of trimethoprim. In brodimoprim, the 4-methoxy group of trimethoprim is replaced with a bromine atom.
As trimethoprim, brodimoprim is a selective inhibitor of bacterial dihydrofolate reductase.[1]
[edit] References
- ^ Thomson CJ (1993). "Trimethoprim and brodimoprim resistance of gram-positive and gram-negative bacteria". J Chemother 5 (6): 45864. PMID 8195838.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||
